UK Housing Market Gains Momentum in Early 2026 as Mortgage Rates Fall 
Wall Street Slips as Tech Stocks Slide on AI Spending Fears and Earnings Concerns 
Asian Currencies Hold Firm as Dollar Rebounds on Fed Chair Nomination Hopes 
Copper Prices Hit Record Highs as Metals Rally Gains Momentum on Geopolitical Tensions 
UK Vehicle Production Falls Sharply in 2025 Amid Cyberattack, Tariffs, and Industry Restructuring 
Oil Prices Surge Toward Biggest Monthly Gains in Years Amid Middle East Tensions 
Gold Prices Hit Record High Above $5,500 as Iran Strike Fears Fuel Safe-Haven Demand 
Asian Currencies Trade Flat as Dollar Retreats After Fed Decision 
Philippine Economy Slows in Late 2025, Raising Expectations of Further Rate Cuts 
Gold and Silver Prices Plunge as Trump Taps Kevin Warsh for Fed Chair 
Trump Threatens 50% Tariff on Canadian Aircraft Amid Escalating U.S.-Canada Trade Dispute 
Canada’s Trade Deficit Jumps in November as Exports Slide and Firms Diversify Away From U.S. 
Bank of Canada Holds Interest Rate at 2.25% Amid Trade and Global Uncertainty 
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster 
Trump to Announce New Federal Reserve Chair Pick as Powell Replacement Looms 
Asia Stocks Pause as Tech Earnings, Fed Signals, and Dollar Weakness Drive Markets 
Swiss pharmaceutical leader Roche confirmed it has no plans for layoffs, emphasizing a healthy business outlook. CEO Thomas Schinecker highlighted steady research funding and workforce stability despite global economic challenges in Europe and China, as well as setbacks in cancer drug development.
Roche Maintains Workforce Stability Amid Market Challenges
Roche, a Swiss pharmaceutical corporation, does not intend to reduce its workforce, and the company's business is doing well. According to a statement made by CEO Thomas Schinecker, which was published in a Swiss publication on Sunday, Investing.com shares.
The stock price of Roche has dropped significantly below the highs it reached in April 2022, and the CEO was questioned about the company's plans for personnel in light of recent setbacks in the company's efforts to produce pharmaceuticals to cure a variety of illnesses, including cancer.
Schinecker responded to a question about whether or not the company was preparing to lay off employees by saying, "The number of workers is constant to slightly increasing," during an interview with the NZZ am Sonntag.
Research and Development Budgets Remain Steady
"I can say with certainty that we have a very healthy business. And we don't have a growth problem either," he remarked, pointing out that Roche's funding for research and development was consistent and not expanding. He also included this information in his statement.
When Schinecker was asked when Roche's intended anti-obesity medicine would be available for purchase, he responded that it may be as early as 2029 or perhaps earlier.
European Economic Struggles Create Headwinds for Recovery
While discussing the forecast for the coming year in a broader sense, particularly in light of the recent difficulties that the German economy has been experiencing, the CEO of Roche stated that Europe still faced problems.
"There's some economic growth in the United States, but things are more difficult in China at the moment," he explained to reporters. "And in Europe it will take some time before we get out of this."
